| Citation: |
WANG Jing, JIA Jinghao, LIU Jingjing, CUI Zhichao, XIONG Wei, WANG Xiaohong. Clinical Observation of Apatinib in Treatment of Refractory Advanced Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(11): 861-865. DOI: 10.3971/j.issn.1000-8578.2020.19.1305
|
To evaluate the clinical efficacy and safety of apatinib in the treatment of advanced breast cancer(ABC) patients refractory to multiline treatments.
We retrospectively analyzed the clinical data of 29 ABC patients after the failure of multi-line treatments. Patients were treated with apatinib 500 mg/d orally. The clinical efficacy and adverse effects were evaluated. Symptomatic treatment and nursing care were given when the adverse effects were ≥grade Ⅲ and apatinib was suspended if not get relieved. When the adverse effects were ≤gradeⅠ, apatinib was administrated with reduced dosage of 250mg/d.
Among 29 patients, there was no case with complete remission, 11(37.9%) patients with partial remission (PR), 13(44.8%) cases with stable disease (SD) and 5(17.2%) patients with progressive disease (PD). The disease control rate (PR+SD) was 82.8% (24/29). The median progression-free survival time (mPFS) was 126 days. The most common adverse effects were secondary hypertension(27.59%), hand-foot syndrome(20.69%), Secondary proteinuria(17.24%), nausea and fatigue(13.79%), Secondary oral mucositis(17.24%) and diarrhea(10.24%). Most of the side effects were degreeⅠ-Ⅱ. Log-rank univariate analysis showed a mPFS of 267 days for Luminal B(HER2-) ABC patients and 126 days for triple-negative group, compared with 33 days for HER2+ ABC patients (P=0.057). Patients with secondary hypertension or transient proteinuria had significantly longer mPFS than those without these adverse effects (P=0.025, P=0.058). Cox regression analysis identified molecular typing, secondary hypertension and proteinuria as the independent influence factors for mPFS of ABC patients treated with apatinib.
Apatinib has relatively high DCR and PFS in the treatment of Luminal B (HER2-) and triple-negative MBC patients, and adverse reactions could be controlled.
| [1] |
Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2012, 23 suppl 7: vii 11-19.
|
| [2] |
Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis[J]. Nature, 2011, 473(7347): 298-307. doi: 10.1038/nature10144
|
| [3] |
Huang L, Wei Y, Shen S, et al. Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients[J]. Oncotarget, 2017, 8(17): 29346-20354. doi: 10.18632/oncotarget.12897
|
| [4] |
Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia[J]. Cancer Cell, 2014, 26(5): 605-622. doi: 10.1016/j.ccell.2014.10.006
|
| [5] |
Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies[J]. BMC Cancer, 2010, 10: 529. doi: 10.1186/1471-2407-10-529
|
| [6] |
Anderson BO, Shyyan R, Eniu A, et al. Breast cancer in limited-resource countries: an overview of the breast health global initiative 2005 guidelines[J]. Breast J, 2006, 12 Suppl 1: S3-S15. http://europepmc.org/abstract/MED/16430397
|
| [7] |
Verheul HMW, Voest EE, Schlingemann RO. Are tumours angiogenesis-dependent?[J]. J Pathol, 2004, 202(1): 5-13. doi: 10.1002/path.1473
|
| [8] |
Rossari JR, Metzger-Filho O, Paesmans M, et al. Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase Ⅲ Studies and a Critical Reappraisal of Available Evidence[J]. J Oncol, 2012, 2012: 417673. http://www.ncbi.nlm.nih.gov/pubmed/23008712
|
| [9] |
Vrdoljak E, Marschner N, Zielinski C, et al. Final results of the TANIA randomised phase Ⅲ trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer[J]. Ann Oncol, 2016, 27(11): 2046-2052. doi: 10.1093/annonc/mdw316
|
| [10] |
Drooger JC, van Tinteren H, de Groot SM, et al. A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial[J]. Cancer, 2016, 122(19): 2961-2970. doi: 10.1002/cncr.30141
|
| [11] |
Martín M, Loibl S, Hyslop T, et al. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials[J]. Eur J Cancer, 2019, 117: 91-98. doi: 10.1016/j.ejca.2019.06.002
|
| [12] |
张化芝, 李晓双, 郭晓烨, 等.阿帕替尼通过抑制糖酵解途径对乳腺癌MDA-MB-231细胞增殖抑制及凋亡的作用[J].肿瘤防治研究, 2019, 46(5): 401-405. doi: 10.3971/j.issn.1000-8578.2019.18.1422
Zhang HZ, Li XS, Guo XY, et al. Apatinib Suppresses Proliferation and Induced Apoptosis of Human Breast Cancer Cell Line MDA-MB-231 Through Glycolytic Inhibition[J]. Zhong Liu Fang Zhi Yan Jiu, 2019, 46(5): 401-405. doi: 10.3971/j.issn.1000-8578.2019.18.1422
|
| [13] |
Gao Z, Shi M, Wang Y, et al. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2[J]. Pathol Res Pract, 2019, 215(7): 152422. doi: 10.1016/j.prp.2019.04.014
|
| [14] |
Hu X, Zhang J, Xu B, et al. Multicenter phase Ⅱ study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer[J]. Int J Cancer, 2014, 135(8): 1961-1969. doi: 10.1002/ijc.28829
|
| [15] |
Hu X, Cao J, Hu W, et al. Multicenter phase Ⅱ study of apatinib in non-triple-negative metastatic breast cancer[J]. BMC Cancer, 2014, 14: 820. doi: 10.1186/1471-2407-14-820
|
| [16] |
Lin Y, Wu Z, Zhang J, et al. Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment[J]. Tumour Biol, 2017, 39(6): 1010428317711033. http://europepmc.org/abstract/MED/28639910
|
| [17] |
Zhu A, Yuan P, Wang J, et al. Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study[J]. Oncol Lett, 2019, 17(6): 4768-4778. http://www.researchgate.net/publication/332165686_Apatinib_combined_with_chemotherapy_in_patients_with_previously_treated_advanced_breast_cancer_An_observational_study
|
| [18] |
Li Y, Zhou Y, Wang Y, et al. Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple negative breast cancer as third-line therapy A retrospective study[J]. Medicine (Baltimore), 2018, 97(36): e12222. doi: 10.1097/MD.0000000000012222
|
| [19] |
秦叔逵, 李进.阿帕替尼治疗胃癌的临床应用专家共识[J].临床肿瘤学杂志, 2015, 20(9): 841-847. http://www.cnki.com.cn/Article/CJFDTotal-LCZL201509014.htm
Qin SQ, Li J. Expert consensus on the clinical application of apatinib for gastric cancer[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2015, 20(9): 841-847. http://www.cnki.com.cn/Article/CJFDTotal-LCZL201509014.htm
|
| [20] |
Sun D, Hou H, Zhang C, et al. The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis[J]. Onco Targets Ther, 2018, 11: 6539-6554. doi: 10.2147/OTT.S176429
|
| [21] |
Fan M, Zhang J, Wang Z, et al. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGFdependency of advanced breast cancer in anti-angiogenic therapy[J]. Breast Cancer Res Treat, 2014, 143(1): 141-151. doi: 10.1007/s10549-013-2793-6
|
| [1] | ZHOU Hairong, WANG Weiwei, LUO Pengfei, HONG Xin. Trend of Colorectal Cancer Burden in China from 1990 to 2019[J]. Cancer Research on Prevention and Treatment, 2024, 51(2): 115-120. DOI: 10.3971/j.issn.1000-8578.2024.23.0883 |
| [2] | LIN Hao, HU Ting, WANG Chaoyang, ZHANG Haibao, JU Jiahua, YU Yongjiang. Application of Clinical Prediction Models for Postoperative Complications of Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(9): 908-912. DOI: 10.3971/j.issn.1000-8578.2023.23.0293 |
| [3] | GAO Jingru, LI Jiaxin, QIAO Youlin, ZHANG Xi, ZHANG Shaokai, XU Huifang, HUA Yunqi, HAO Jinqi, FU Ying, SHI Zhengyang, YU Yanqin, SHI Jihai. Cognition of Colorectal Cancer-related Knowledge and Influencing Factors of Patients with Middle- and Advanced-stage Colorectal Cancer in Inner Mongolia[J]. Cancer Research on Prevention and Treatment, 2023, 50(6): 603-608. DOI: 10.3971/j.issn.1000-8578.2023.22.1248 |
| [4] | ZHONG Haojie, LUO Wenhui, LIU Yongjia, LIN Da, XUE Lanfeng, CHEN Yu. Progress in Follow-up of High-risk Factors After Endoscopic Resection of Colorectal Tumors[J]. Cancer Research on Prevention and Treatment, 2019, 46(4): 371-375. DOI: 10.3971/j.issn.1000-8578.2019.18.1406 |
| [5] | ZHANG Yachen, LIANG Di, JIN Jing, LI Daojuan, LIU Congmin, GAO Zhaoyu, HE Yutong. Research Progress on Risk Factors for Lung Cancer in Nonsmokers[J]. Cancer Research on Prevention and Treatment, 2017, 44(7): 501-505. DOI: 10.3971/j.issn.1000-8578.2017.16.1627 |
| [6] | PENG Xian-e, JIANG Ying-ying, SHI Xi-shun, ZHENG Xiao-yian, XIAO Jing-rong, LIN Xu. Case-control Study on Risk Factors of Colorectal Cancer in Fujian Province[J]. Cancer Research on Prevention and Treatment, 2009, 36(09): 794-796. DOI: 10.3971/j.issn.1000-8578.2009.09.023 |
| [7] | ZHAO Jun-shi, HUANG Min-zhu, WU Xin-yin, HE Xiao-wei. A Case-control Study on Risk Factors of Colonic Cancer[J]. Cancer Research on Prevention and Treatment, 2008, 35(07): 524-526. DOI: 10.3971/j.issn.1000-8578.1486 |
| [8] | ZHU Zhao-yang, ZHANG Zhi-feng, LI Chang-feng, WAN Jun, DUAN Ji-jun. Analysis on Risk Factors of Lung Cancer in the City Zone of Wuhan[J]. Cancer Research on Prevention and Treatment, 2007, 34(08): 633-635. DOI: 10.3971/j.issn.1000-8578.2351 |
| [9] | ZENG Zhuan-ping, CHEN Feng, LIU Bin, HUANG Man-ni, ZHANG Xun, PAN Qin-jing, ZHAO Fang-hui, RONG Shou-de, QIAO You-lin. Analysis of Risk Factors for Cervical Cancer in Yangcheng County[J]. Cancer Research on Prevention and Treatment, 2004, 31(03): 178-181. DOI: 10.3971/j.issn.1000-8578.1020 |
| [10] | Liang XIE, Chang LIU, Jian-hua LI, Jian-hui LI, Xin HAO, Hai-yang HUA. Risk factor analysis and risk prediction modeling of rectal neuroendocrine tumors[J]. Cancer Research on Prevention and Treatment. DOI: 10.3971/j.issn.1000-8578.2025.24.1089 |
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: